Phaseline

Targets › CXCL12

CXCL12 (Stromal cell-derived factor 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Chemoattractant active on T-lymphocytes and monocytes but not neutrophils. Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. (UniProt, P48061)

Open in Phaseline: the race on CXCL12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TME PharmaOlaptesed Pegol (A12)
Stromal cell-derived factor 1 inhibitor
CXCL12Phase 1GlioblastomaDec 2028

Conditions

Glioblastoma (1)

Modalities

mixed (1)

Companies

TME Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.